We evaluated the potential usefulness of 1251-labeledphydroxybupropion in a direct radioimmunoassay for bupropion in human plasma as compared with a currently used [3H)bupropion dextran-coated charcoal method. In both radioimmunoassay methods succinoylpropylbupropion antiserum was used that was highly specific for unchanged drug, sure bupropion concentrations in rodent plasma and brain (6). However, the presence in these samples of cross-reacting metabolites, including a compound tentatively identified as p.hydroxybupropion, necessitated solvent extraction from an alkaline medium before radioimmunoassay.
sure bupropion concentrations in rodent plasma and brain (6). However, the presence in these samples of cross-reacting metabolites, including a compound tentatively identified as p.hydroxybupropion, necessitated solvent extraction from an alkaline medium before radioimmunoassay.
We also found that human urine contains sufficient concentrations of unidentified cross-reactingmetabolites to necessitate extraction of bupropion before radloimmunoassay by the
[3H]bupropion dextran-coated charcoal method (5), whereas the direct analysis of human plasma samples showed only slight interferences (4).
Here we describe the development of an '251-labeled phydroxybupropion-based radioimmunoassay in which polyethylene glycol precipitation is used to separate antibodybound from free radioligand, and report the application of this procedure to directhuman plasma analyses. We compared results obtained by both radioimmunoassay methods for 89 plasma samples collected from five subjects over a 60-h period after they ingested 100 mg of bupropion hydrochloride. We found that the method involving 'WI-labeled phydroxybupropion and polyethylene glycol affordedgreater convenience and assay sensitivity without sacrificing specificity or precision. Total-count and background tubes contained [3Hlbupropion, blank human plasma, and G-PBS. After incubating samples overnight at 4#{176}C, we added 0.5 mL of a well-stirred, ice-cold suspension of dextran-coated charcoal to all except the totalcount tubes. The tube contents were vortex-mixed, incubated at 4#{176}C for 5 mm, and centrifuged ( 1000 x g)for 15 mm at 4#{176}C. Supernates were decanted into 10 mL of scintillation cocktail and antibody-bound radioactivity was quantified with a Model 2660 scintillation spectrometer (Packard Instrument Co., Downers Grove, IL 60515). The titer of the antiserum used in these studies with [3Hlbupropion (i.e., the antiserum dilution that bound specifically 40% of the total radioligand added) was 1:5000.
MaterIals and Methods

Materials
Antisera titrations with '251-labeled p-hydroxybupropion were performed by incubating, in glass tubes, 0.7 mL of antisera dilutions in BSA-PBS with 0.2 mL of radioligand (80 000 cpm) in BSA-PBS and 0.1 mL of blank human plasma as described above. The total-counttubes contained only '251-labeled p-hydroxybupropion; the background tubes contained labeled p-hydroxybupropion, blank human plasma, and BSA-PBS. We added 1.0 mL of polyethylene glycol solution to all except the total-count tubes, vortex-mixed the tube contents thoroughly, and centrifuged the tubes at 1000 x g and 4#{176}C for 30 mm. Supernates were decanted, the inverted tubes were allowed to drain for 30 mm, and the antibody-bound radioactivity in the pellets was quantified within a Model 5260 Auto-Gamma scintillation spectrome-
Co.).The titer of the antiserum used in these studies with '251-labeled p-hydroxybupropion (i.e., the dilution that produced 50% of maximum specific radioligand binding) was 1:12 000. Antisera specificity. The procedures were similar to those described for antisera titrations, except that the blank human plasma was replaced by increasing concentrations of bupropion and compounds of interest in 0.1 mL of human plasma, and antisera were used at the determined titers. Standard curves for each compound were expressed as the percentage BIB0 vs log drug concentration, in which B0 represents the background corrected amount (counts) of radioligand bound in the absence of unlabeled bupropion and B is the amount bound at a given drug concentration. Cross reactivities were expressed as the percentage ratio of the bupropion concentration required to produce 50% inhibition of radioligand binding to antiserum (IC) to that of each compound of interest (7).
Analysis of unknown samples.
We prepared a series of bupropion standard solutions-0. 19 to 25 pg/L for the 125j radioimmunoassay and 0.39 to 50 g/L for the 3H assay-in 0.1 mL of blank human plasma, and incubated them with the respective radioligands and appropriately diluted antiserum as described above. The total-countand background tubes for each assay method also were as described above. Unknown samples, or control samples containing known amounts of bupropion in human plasma (0.1 mL), diluted appropriately with blank plasma to enter the range of the assay, also were incubated with radioligand and antiserum.
We assayed most controls and unknown samples at two dilutions. After overnight incubation, antibody-bound and free '251-labeled p-hydroxybupropion
and f3H]bupropion fractions were separated, and the standard curves were prepared as described above.
Human Study
After giving informed consent, five healthy men fasted overnight before and for 6 h after ingesting, with 200 mL of water, two 50-mg tablets of bupropion hydrochloride. Blood Plasma samples were collected immediately and stored at -20 #{176}C until analyzed by both of the radioimmunoassay methods. We used orthogonal regression analysis (8) to compare bupropion plasma concentration data determined by the two methods, and calculated the areas under the bupropion plasma concentration-time curves (AUC) by the trapezoidal rule method (9).
Results
Assay Characteristics
Specificity. Relative specificities of the 13H]bupropion and 1251-labeled p-hydroxybupropion radioimmunoassays are summarized in Table 1 . Clearly, both radioimmunoassay methods were highly specific for bupropion, with known bupropion metabolites (compounds ifi-VI, m-chlorobenzoic acid, and m-chlorohippuric acid) (10, 11) cross reacting only very weakly ( 0.3%).
Only p-hydroxybupropion (VU), which has not been identified as a bupropion metabolite in human plasma, cross reacted significantly with the succinoylpropylbupropion antiserum used in these studies. Cross reactivities with various drugs, including catecholamines, narcotic analgesics, and tricyclic antidepressants, were <0.001% when tested with [3Hlbupropion (4). Confirmation of the specificity of the [3Hlbupropion radioimmunoassay was provided by the good agreement (slope = 1.15, r = between bupropion concentrations in the five subjects, as determined by the two methods, demonstrated the suitability of the 'I-labeled p-hydroxybupropion method for direct plasma analyses.
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